Detection and treatment of pheochromocytomas and paragangliomas: Current standing of MIBG scintigraphy and future role of PET imaging

Quarterly Journal of Nuclear Medicine and Molecular Imaging

Volumn 52, Issue 4, 2008, Pages 419-429

  Havekes, B ^a,b   Lai, E W ^a   Corssmit, E P M ^b   Romijn, J A ^b   Timmers, H J L M ^c   Pacak, Karel ^a  

^a EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^c RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Paragangliomas; Pheochromocytomas; Radionuclide imaging; Tomography, emission computed

Indexed keywords

(3 IODOBENZYL)GUANIDINE; (3 IODOBENZYL)GUANIDINE I 123; (3 IODOBENZYL)GUANIDINE I 131; ANTIDEPRESSANT AGENT; CAFFEINE; CALCIUM CHANNEL BLOCKING AGENT; CARBON HYDROXYEPHEDRINE C 11; EPHEDRINE; FLUORODEOXYGLUCOSE F 18; FLUORODIHYDROXYPHENYLALAMINE F 18; FLUORODOPAMINE F 18; IODINE 123; IODINE 131; LABETALOL; NORADRENALIN TRANSPORTER; PHENYLEPHRINE; PHENYLPROPANOLAMINE; PSEUDOEPHEDRINE; RADIOPHARMACEUTICAL AGENT; RESERPINE; SEROTONIN UPTAKE INHIBITOR; TRICYCLIC ANTIDEPRESSANT AGENT; UNCLASSIFIED DRUG;

ADRENAL SCINTISCANNING; ADRENERGIC SYSTEM; BLOOD DISEASE; BONE MARROW DEPRESSION; CATECHOLAMINE RELEASE; DIAGNOSTIC ACCURACY; DOSE RESPONSE; DRUG ALCOHOL INTERACTION; DRUG HALF LIFE; DRUG UPTAKE; GENOTYPE PHENOTYPE CORRELATION; HUMAN; LEUKOPENIA; NAUSEA; NONHUMAN; PARAGANGLIOMA; PHEOCHROMOCYTOMA; PHEOCHROMOCYTOMA CELL; POSITRON EMISSION TOMOGRAPHY; RADIOSENSITIVITY; REVIEW; SINGLE DRUG DOSE; THROMBOCYTOPENIA; TUMOR LOCALIZATION;

3-IODOBENZYLGUANIDINE; HUMANS; IODINE RADIOISOTOPES; PARAGANGLIOMA; PHEOCHROMOCYTOMA; POSITRON-EMISSION TOMOGRAPHY;

EID: 60549098083     PISSN: 18244785     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (98)

1. Pacak K, Eisenhofer G, Ahlman H, Bornstein SR, Gimenez-Roqueplo AP, Grossman AB et al. Pheochromocytoma: recommendations for clinical practice from the First International Symposium. October 2005. Nat Clin Pract Endocrinol Metab 2007;3:92-102.
2. Lenders JW, Eisenhofer G, Mannelli M, Pacak K. Phaeochromocytoma. Lancet 2005;366:665-75.
3. Jaques S Jr, Tobes MC, Sisson JC. Sodium dependency of uptake of norepinephrine and m-iodobenzylguanidine into cultured human pheochromocytoma cells: evidence for uptake-one. Cancer Res 1987;47:3920-8.
4. Lynn MD, Shapiro B, Sisson JC, Beierwaltes WH, Meyers LJ, Ackerman R et al. Pheochromocytoma and the normal adrenal medulla: improved visualization with I-123 MIBG scintigraphy. Radiology 1985;155:789-92.
5. Neumann HP, Bausch B, McWhinney SR, Bender BU, Gimm O, Franke G et al. Germ-line mutations in nonsyndromic pheochromocytoma. N Engl J Med 2002;346:1459-66.
6. Baysal BE, Ferrell RE, Willett-Brozick JE, Lawrence EC, Myssiorek D, Bosch A et al. Mutations in SDHD, a mitochondrial complex II gene, in hereditary paraganglioma. Science 2000;287:848-51.
7. Baysal BE. On the association of succinate dehydrogenase mutations with hereditary paraganglioma. Trends Endocrinol Metab 2003;14:453-9.
8. Benn DE, Gimenez-Roqueplo AP, Reilly JR, Bertherat J, Burgess J, Byth K et al. Clinical presentation and penetrance of pheochromocytoma/ paraganglioma syndromes. J Clin Endocrinol Metab 2006;91:827-36.
9. Neumann HP, Pawlu C, Peczkowska M, Bausch B, McWhinney SR, Muresan M et al. Distinct clinical features of paraganglioma syndromes associated with SDHB and SDHD gene mutations. JAMA 2004;292:943-51.
10. Timmers HJ, Kozupa A, Eisenhofer G, Raygada M, Adams KT, Solis D et al. Clinical presentations, biochemical phenotypes, and genotype-phenotype correlations in patients with succinate dehydrogenase subunit b-associated pheochromocytomas and paragangliomas. J Clin Endocrinol Metab 2007;92:779-86.
11. Havekes B, Corssmit EP, Jansen JC, van der Mey AG, Vriends AH, Romijn JA. Malignant paragangliomas associated with mutations in the succinate dehydrogenase D gene. J Clin Endocrinol Metab 2007;92:1245-8.
12. Timmers HJ, Pacak K, Bertherat J, Lenders JW, Duet M, Eisenhofer G et al. Mutations associated with succinate dehydrogenase D-related malignant paragangliomas. Clin Endocrinol (Oxf) 2008;68:561-6.
13. 131I]iodobenzylguanidine. J Nucl Med 1980;21:349-53.
14. Sisson JC, Frager MS, Valk TW, Gross MD, Swanson DP, Wieland DM et al. Scintigraphic localization of pheochromocytoma. N Engl J Med 1981;305:12-7.
15. 131I] meta-iodobenzylguanidine: concise communication. J Nucl Med 1981;22:358-64.
16. Bravo EL. Evolving concepts in the pathophysiology, diagnosis, and treatment of pheochromocytoma. Endocr Rev 1994;15:356-68.
17. Sisson JC, Shulkin BL. Nuclear medicine imaging of pheochromocytoma and neuroblastoma. Q J Nucl Med 1999;43:217-23.
18. 131I]-metaiodobenzylguanidine scintigraphy. Int J Urol 1999; 6:119-24.
19. Shulkin BL, Shapiro B, Francis IR, Dorr R, Shen SW, Sisson JC. Primary extra-adrenal pheochromocytoma: positive I-123 MIBG imaging with negative I-131 MIBG imaging. Clin Nucl Med 198 11:851-4.
20. Shapiro B, Gross MD, Shulkin B. Radioisotope diagnosis and therapy of malignant pheochromocytoma. Trends Endocrinol Metab 2001;12:469-75.
21. 123I-MIBG scintigraphy in localizing pheochromocytomas: a prospective study. Nucl Med Commun 2006;27:583-7.
22. Cecchin D, Lumachi F, Marzola MC, Opocher G, Scaroni C, Zucchetta P et al. A meta-iodobenzylguanidine scintigraphic scoring system increases accuracy in the diagnostic management of pheochromocytoma. Endocr Relat Cancer 2006;13:525-33.
23. Nakatani T, Hayama T, Uchida J, Nakamura K, Takemoto Y, Sugimura K. Diagnostic localization of extra-adrenal pheochromocytoma: comparison of (123)I-MIBG imaging and (131)I-MIBG imaging. Oncol Rep 2002;9:1225-7.
24. Nielsen JT, Nielsen BV, Rehling M. Location of adrenal medullary pheochromocytoma by I-123 metaiodobenzylguanidine SPECT. Clin Nucl Med 1996;21:695-9.
25. 123I]iodobenzylguanidine: concise communication. J Nucl Med 1984;25:436-40.
26. Elgazzar AH, Gelfand MJ, Washburn LC, Clark J, Nagaraj N, Cummings D et al. I-123 MIBG scintigraphy in adults. A report of clinical experience. Clin Nucl Med 1995;20:147-52.
27. Lindberg S, Fjalling M, Jacobsson L, Jansson S, Tisell LE. Methodology and dosimetry in adrenal medullary imaging with iodine-131 MIBG. J Nucl Med 1988;29:1638-43.
28. Nakajo M, Shapiro B, Copp J, Kalff V, Gross MD, Sisson JC et al. The normal and abnormal distribution of the adrenomedullary imaging agent m-[I-131]iodobenzylguanidine (I-131 MIBG) in man: evaluation by scintigraphy. J Nucl Med 1983;24:672-82.
29. Yung BC, Loke TK, Tse TV, Tsang MW, Chan JC. Sporadic bilateral adrenal medullary hyperplasia: apparent false positive MIBG scan and expected MRI findings. Eur J Radiol 2000;36:28-31.
30. Eisenhofer G. The role of neuronal and extraneuronal plas mamembrane transporters in the inactivation of peripheral catecholamines. Pharmacol Ther 2001;91:35-62.
31. Solanki KK, Bomanji J, Moyes J, Mather SJ, Trainer FJ, Britton KE. A pharmacological guide to medicines which interfere with the biodistribution of radiolabelled meta-iodobenzylguanidine (MIBG). Nucl Med Commun 1992;13:513-21.
32. van der Harst E, de Herder WW, Bruining HA, Bonjer HJ, de Krijger RR, Lamberts SW et al. [(123)I]metaiodobenzylguanidine and [(111)In]octreotide uptake in benign and malignant pheochromocytomas. J Clin Endocrinol Metab 2001;86:685-93.
33. Van Der Horst-Schrivers AN, Jager PL, Boezen HM, Schouten JP, Kema IP, Links TP. Iodine-123 metaiodobenzylguanidine scintigraphy in localising phaeochromocytomas - experience and meta-analysis. Anticancer Res 2006;26:1599-604.
34. 123I-metaiodobenzylguanidine (MIBG) scintigraphy for the detection of adrenal and extra-adrenal phaeochromocytomas: CT and MRI correlation. Clin Endocrinol (Oxf) 2008;69:181-8.
35. Mackenzie IS, Gurnell M, Balan KK, Simpson H, Chatterjee K, Brown MJ. The use of 18-fluoro-dihydroxyphenylalanine and 18-fluorodeoxyglucose positron emission tomography scanning in the assessment of metaiodobenzylguanidine-negative phaeochromocytoma. Eur J Endocrinol 2007;157:533-7.
36. 18F]fluorodopamine positron emission tomography in the localization of adrenal pheochromocytoma associated with von Hippel-Lindau syndrome. Eur J Endocrinol 2007; 156:483-7.
37. van Houtum WH, Corssmit EP, Douwes Dekker PB, Jansen JC, van der Mey AG, Brocker-Vriends AH et al. Increased prevalence of catecholamine excess and phaeochromocytomas in a well-defined Dutch population with SDHD-linked head and neck paragangliomas. Eur J Endocrinol 2005;152:87-94.
38. Timmers HJ, Kozupa A, Chen CC, Carrasquillo JA, Ling A, Eisenhofer G et al. Superiority of fluorodeoxyglucose positron emission tomography to other functional imaging techniques in the evaluation of metastatic SDHB-associated pheochromocytoma. and paraganglioma. J Clin Oncol 2007;25:2262-9.
39. 18F DOPA whole body PET - initial results. Radiology 2002;222:507-12.
40. Greenblatt DY, Shenker Y, Chen H. The utility of metaiodobenzylguanidine (MIBG) scintigraphy in patients with pheochromocytoma. Ann Surg Oncol 2008;15:900-5.
41. Pacak K, Ilias I, Adams KT, Eisenhofer G. Biochemical diagnosis, localization and management of pheochromocytoma: focus on multiple endocrine neoplasia type 2 in relation to other hereditary syndromes and sporadic forms of the tumour. J Intern Med 2005;257:60-8.
42. Shulkin BL, Koeppe RA, Francis IR, Deeb GM, Lloyd RV, Thompson NW. Pheochromocytomas that do not accumulate metaiodobenzylguanidine: localization with PET and administration of FDG. Radiology 1993;186:711-5.
43. Shulkin BL, Thompson NW, Shapiro B, Francis IR, Sisson JC. Pheochromocytomas: imaging with 2-[fluorine-18]fluoro-2-deoxy-D-glucose PET. Radiology 1999;212:35-41.
44. Miskulin J, Shulkin BL, Doherty GM, Sisson JC, Burney RE, Gauger PG. Is preoperative iodine 123 meta-iodobenzylguanidine scintigraphy routinely necessary before initial adrenalectomy for pheochromocytoma? Surgery 2003;134:918-22.
45. Ilias I, Shulkin B, Pacak K. New functional imaging modalities for chromaffin tumors, neuroblastomas and ganglioneuromas. Trends Endocrinol Metab 2005;16:66-72.
46. Giammarile F, Baudin E, Tenenbaum F, Lumbroso J, Schlumberger M, Rougier P et al. Somatostatin receptor imaging: a preliminary experience in forty-nine patients. Q J Nucl Med 1995;39:121-3.
47. Kwekkeboom DJ, van UH, Pauw BK, Lamberts SW, Kooij PP, Hoogma RP et al. Octreotide scintigraphy for the detection of paragangliomas. J Nucl Med 1993;34:873-8.
48. Lamberts SW, Reubi JC, Krenning EP. Validation of somatostatin receptor scintigraphy in the localization of neuroendocrine tumors. Acta Oncol 1993;32:167-70.
49. Lastoria S, Maurea S, Vergara E, Acampa W, Varrella P, Klain M et al. Comparison of labeled MIBG and somatostatin analogs in imaging neuroendocrine tumors. Q J Nucl Med 1995;39:145-9.
50. Tenenbaum F, Lumbroso J, Schlumberger M, Mure A, Plouin PF, Caillou B et al. Comparison of radiolabeled octreotide and meta-iodobenzylguanidine (MIBG) scintigraphy in malignant pheochromocytoma. J Nucl Med 1995;36:1-6.
51. Kaltsas G, Korbonits M, Heintz E, Mukherjee JJ, Jenkins PJ, Chew SL et al. Comparison of somatostatin analog and meta-iodobenzylguanidine radionuclides in the diagnosis and localization of advanced neuroendocrine tumors. J Clin Endocrinol Metab 2001; 86:895-902.
52. Pacak K, Eisenhofer G, Goldstein DS. Functional imaging of endocrine tumors: role of positron emission tomography. Endocr Rev 2004;25:568-80.
53. 18F]fluorodeoxyglucose positron emission tomography improve clinical decision making in suspected pheochromocytoma. Ann Surg Oncol 2006;13:187-97.
54. Beyer T, Townsend DW, Blodgett TM. Dual-modality PET/CT tomography for clinical oncology. Q J Nucl Med 2002;46:24-34.
55. Schwaiger M, Kalff V, Rosenspire K, Haka MS, Molina E, Hutchins GD et al. Noninvasive evaluation of sympathetic nervous system in human heart by positron emission tomography. Circulation 1990;82:457-64.
56. Rosenspire KC, Haka MS, Van Dort ME, Jewett DM, Gildersleeve DL, Schwaiger M et al. Synthesis and preliminary evaluation of carbon-11-meta-hydroxyephedrine: a false transmitter agent for heart neuronal imaging. J Nucl Med 1990;31:1328-34.
57. Shulkin BL, Wieland DM, Schwaiger M,Thompson NW, Francis IR, Haka MS et al. PET scanning with hydroxyephedrine: an approach to the localization of pheochromocytoma. J Nucl Med 1992;33:1125-31.
58. Hovevey-Sion D, Eisenhofer G, Kopin IJ, Kirk KL, Chang PC, Szemeredi K et al. Metabolic fate of injected radiolabelled dopamine and 2-fluorodopamine in rats. Neuropharmacology 1990;29:881-7.
59. Pacak K, Linehan WM, Eisenhofer G, Walther MM, Goldstein DS. Recent advances in genetics, diagnosis, localization, and treatment of pheochromocytoma. Ann Intern Med 2001;134:315-29.
60. 18F]fluorodopamine positron emission tomographic (PET) scanning for diagnostic localization of pheochromocytoma. Hypertension 2001;38:6-8.
61. Pacak K, Goldstein DS, Doppman JL, Shulkin BL, Udelsman R, Eisenhofer G. A "pheo" lurks: novel approaches for locating occult pheochromocytoma. J Clin Endocrinol Metab 2001;86:3641-6.
62. 131I]-metaiodobenzylguanidine scintigraphy in the localization of metastatic pheochromocytoma. J Clin Endocrinol Metab 2003;88:4083-7.
63. 18F-fluorodopamine PET. J Nucl Med 2007;48:1940-4.
64. Jager PL, Chirakal R, Marriott CJ, Brouwers AH, Koopmans KP, Gulenchyn KY. 6-L-18F-fluorodihydroxyphenylalanine PET in neuroendocrine tumors: basic aspects and emerging clinical applications. J Nucl Med 2008;49:573-86.
65. 18F-DOPA positron emission tomography for tumour detection in patients with medullary thyroid carcinoma and elevated calcitonin levels. Eur J Nucl Med 2001;28:64-71.
66. 18F dopa PET for detection of gastrointestinal carcinoid tumors. Radiology 2001;220:373-80.
67. 18F-fluoro-L-DOPA in PET of pheochromocytoma and extraadrenal abdominal paraganglioma. J Nucl Med 2007;48:1599-606.
68. 18F-fluorodeoxyglucose PET/CT in cancer imaging. Clin Med 2006;6:240-4.
69. Pauwels EK, Ribeiro MJ, Stoot JH, McCready VR, Bourguignon M, Maziere B. FDG accumulation and tumor biology. Nucl Med Biol 1998;25:317-22.
70. Kelloff GJ, Hoffman JM, Johnson B, Scher HI, Siegel BA, Cheng EY et al. Progress and promise of FDG-PET imaging for cancer patient management and oncologic drug development. Clin Cancer Res 2005;11:2785-808.
71. Eisenhofer G, Bornstein SR, Brouwers FM, Cheung NK, Dahia PL, de Krijger RR et al. Malignant pheochromocytoma: current status and initiatives for future progress. Endocr Relat Cancer 2004;11:423-36.
72. Scholz T, Eisenhofer G, Pacak K, Dralle H, Lehnert H. Clinical review: current treatment of malignant pheochromocytoma. J Clin Endocrinol Metab 2007;92:1217-25.
73. Sisson JC, Shapiro B, Beierwaltes WH, Glowniak JV, Nakajo M, Mangner TJ et al. Radiopharmaceutical treatment of malignant pheochromocytoma. J Nucl Med 1984;25:197-206.
74. 131I]metaiodobenzylguanidine: results from ten years of experience. J Nucl Biol Med 1991;35:269-76.
75. 131I]metaiodobenzylguanidine therapy in the treatment of neural crest tumors. J Nucl Biol Med 1991;35:357-63.
76. Shapiro B, Sisson JC, Shulkin BL, Gross MD, Zempel S. The current status of radioiodinated metaiodobenzylguanidine therapy of neuro-endocrine tumors. Q J Nucl Med 1995;39:55-7.
77. 131I-MIBG therapy in metastatic phaeochromocytoma and paraganglioma. Eur J Nucl Med Mol Imaging 2008;35:725-33.
78. Mundschenk J, Lehnert H. Malignant pheochromocytoma. Exp Clin Endocrinol Diabetes 1998;106:373-6.
79. 131I-MIBG): a comprehensive review of 116 reported patients. J Endocrinol Invest 1997;20:648-58.
80. Sisson JC. Radiopharmaceutical treatment of pheochromocytomas. Ann N Y Acad Sci 2002;970:54-60.
81. Troncone L, Rufini V. Nuclear medicine therapy of pheochromocytoma and paraganglioma. Q J Nucl Med 1999;43:344-55.
82. 131I-metaiodobenzylguanidine therapy for 12 patients with malignant pheochromocytoma. Cancer 2003;98:239-48.
83. 131I-MIBG). Ann N Y Acad Sci 2006; 1073:465-90.
84. 131I]metaiodobenzylguanidine therapy in two patients with malignant pheochromocytoma. J Clin Endocrinol Metab 2005; 90:5888-95.
85. 177Lu-DOTA0, Tyr3]octreotate in patients with paraganglioma, meningioma, small cell lung carcinoma, and melanoma. J Nucl Med 2006;47:1599-606.
86. Duet M, Sauvaget E, Petelle B, Rizzo N, Guichard JP, Wassef M et al. Clinical impact of somatostatin receptor scintigraphy in the management of paragangliomas of the head and neck. J Nucl Med 2003;44:1767-74.
87. Forrer F, Riedweg I, Maecke HR, Mueller-Brand J. Radiolabeled DOTATOC in patients with advanced paraganglioma and pheochromocytoma. Q J Nucl Med Mol Imaging 2008. [Epub ahead of print].
88. Mundschenk J, Unger N, Schulz S, Hollt V, Schulz S, Steinke R et al. Somatostatin receptor subtypes in human pheochromocytoma: subcellular expression pattern and functional relevance for octreotide scintigraphy. J Clin Endocrinol Metab 2003;88:5150-7.
89. Mairs RJ, Cunningham SH, Russell J, Armour A, Owens J, McKellar K et al. No-carrier-added iodine-131-MIBG: evaluation of a therapeutic preparation. J Nucl Med 1995;36:1088-95.
90. Fullerton NE, Boyd M, Ross SC, Pimlott SL, Babich J, Kirk D et al. Comparison of radiohaloanalogues of meta-iodobenzylguanidine (MIBG) for a combined gene- and targeted radiotherapy approach to bladder carcinoma. Med Chem 2005;1:611-8.
91. 211At]MABG. Bioorg Med Chem 2007;15:3430-6.
92. 131I-MIBG. J Nucl Med 2005;46:2112-6.
93. Armour A, Cunningham SH, Gaze MN, Wheldon TE, Mairs RJ. The effect of cisplatin pretreatment on the accumulation of MIBG by neuroblastoma cells in vitro. Br J Cancer 1997;75:470-6.
94. Montaldo PG, Raffaghello L, Guarnaccia F, Pistoia V, Garaventa A, Ponzoni M. Increase of metaiodobenzylguanidine uptake and intracellular half-life during differentiation of human neuroblastoma cells. Int J Cancer 1996;67:95-100.
95. 131I meta-iodobenzylguanidine. Gene Ther 1999;6:1147-52.
96. Mairs RJ, Cunningham SH, Boyd M, Carlin S. Applications of gene transfer to targeted radiotherapy. Curr Pharm Des 2000;6:1419-32.
97. 125I-meta-iodobenzylguanidine uptake in human neuroblastoma cell lines. Eur J Cancer 1999;35:1227-34.
98. 131I]meta-iodobenzylguanidine (MIBG) and cisplatin. Eur J Cancer 1995;31A:606-11.